Physician profile
Michael Seamon
NPI 1669747762
$3,484.44
in general payments reported to CMS, 2019-2025
26 companies · $480 in 2025
The $480 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,206 · 2022: $1,013 · 2023: $391 · 2024: $395 · 2025: $480.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,265.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $661.59 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $558.91 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $392.51 | 2021-2025 | Camzyos, Eliquis |
| Pfizer INC. | $387.60 | 2021-2024 | |
| Amgen INC. | $297.86 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $176.22 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $162.01 | 2021-2024 | Verquvo |
| Alnylam Pharmaceuticals INC. | $121.72 | 2021-2025 | Amvuttra |
| Abbott Laboratories | $101.62 | 2022-2025 | Cardiomems, Navitor |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $84.45 | 2021-2023 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.34 | 2021-2022 | |
| Philips North America LLC | $74.68 | 2022-2025 | Ecc Solutions, Extended Holter |
| Irhythm Technologies, INC. | $50.29 | 2021-2024 | Zio Xt Patch, Zio Monitor |
| Kiniksa Pharmaceuticals International, Plc | $46.44 | 2024 | Arcalyst |
| Astrazeneca Pharmaceuticals LP | $45.86 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bridgebio Pharma, INC. | $32.78 | 2025 | Attruby |
| Boston Scientific Corporation | $32.70 | 2025 | Bodyguardian |
| Lexicon Pharmaceuticals, INC. | $29.28 | 2023-2024 | Inpefa |
| Esperion Therapeutics, INC. | $25.99 | 2021-2023 | Nexletol |
| Novo Nordisk INC | $23.38 | 2023 | Ozempic |
| Medtronic, INC. | $23.03 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $20.94 | 2024 | Evkeeza |
| Cvrx, INC. | $20.67 | 2025 | Barostim Neo System |
| Biotronik INC. | $17.69 | 2022 | |
| Amarin Pharma, INC. | $12.27 | 2021 | |
| Vivaquant INC, Dba Rhythm Express | $8.61 | 2025 | Rhythm Express |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Seamon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.